Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer

Zhenhua Huang¹†, Yantan Liu¹†, Chen Yang¹, Xiaoyin Li¹, Changqie Pan¹, Jinjun Rao², Nailin Li³, Wangjun Liao¹ and Li Lin¹*

Abstract

Background: Gastric cancer is common in developing regions, and we hope to find out an economical but practical prognostic indicator. It was reported that pre-treatment peripheral neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as well as differentiation status, are associated with cancer progression. Hence, we introduced a novel combined Neutrophil/platelet/lymphocyte/differentiation Score (cNPLDS) to improve the prediction value of palliative chemotherapeutic response in advanced gastric cancer.

Methods: According to statistical sample size estimation, 136 primary diagnosed unresectable advanced patients were included for a retrospective study. The follow-up end-point was progression free survival (PFS) during the first-line palliative chemotherapy. Differentiation stratified patients into well, medium and poor groups by score 1 to 3, while patients with neither elevated NLR and PLR, only one elevated, or both elevated were of the combined NLR-PLR score (cNPS) 1 to 3, respectively. The cNPLDS was calculated by multiplying the tumor differentiation score and cNPS.

Results: Determined by the receiver operating characteristic (ROC) curve, the optimal cut-off points for NLR and PLR were 3.04 and 223. Through univariate analysis and survival analysis, poor differentiation, high NLR, high PLR, high cNPS, and high cNPLDS respectively indicated inferior PFS during the first-line palliative chemotherapy. Patients were further classified into low to high risk groups by cNPLDS. Groups of elevated NLR, PLR, cNPS, and cNPLDS showed lower disease control rate. Compared to other parameters, cNPLDS significantly improved the accuracy in predicting the first-progression.

Conclusions: This study indicates that the novel parameter cNPLDS is superior to NLR or PLR alone, or even cNPS, in predicting the first-line chemosensitivity in advanced gastric cancer.

Keywords: Gastric cancer, Chemosensitivity, Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, Tumor differentiation

* Correspondence: linli001@smu.edu.cn
† Equal contributors
¹Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Gastric cancer is one of the most common malignant tumors in east Asia. In China, the 5-year survival rate of this disease is relatively lower because a large proportion of gastric cancer patients were already at advanced stage when diagnosis [1], and about 500,000 people died from it during the year 2015 [2]. At present, the major treatment option for advanced unresectable gastric cancer is chemotherapy. Unfortunately, doctors have to face that many patients give up further treatments just because of the economic reasons in the less developed regions. Previous studies have demonstrated that some cancer endogenous factors, such as differentiation status [3, 4] or certain genes expression [4–6], may influence the efficiency of chemotherapy. However, we still know very little about whether there are other affordable pre-treatment factors can better predict progression free survival in advanced unresectable gastric cancer patients, which may help to optimize the treatment strategies.

It was reported that systemic inflammatory response plays important roles in the progression of various cancers [7–9]. Circulating inflammatory cells can release many biological active factors and thus lead to tumor growth, progression, and metastasis [10–12]. Previously, we have demonstrated a close cooperation between neutrophils, platelets and lymphocytes in basic experiments [13, 14]. In clinical studies, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were adopted for prognosis evaluation in many cancers [15–23]. Recently, a study showed that preoperative combined NLR and PLR Score (cNPS) better predicted the postoperative survival in early stage gastric cancer than NLR or PLR alone [21]. However, it remains unclear whether cNPS has better prognostic prediction value for the first-line chemotherapy in advanced unresectable gastric cancer patients. Moreover, cNPS only implied the systemic inflammatory status. We suppose that taking the endogenous factor (e.g. differentiation status) into account together may further improve the prediction efficiency.

Therefore, we introduce a novel combined Neutrophil/platelet/lymphocyte/differentiation Score (cNPLDS), together with cNPS and other clinical indices, to find out the optimum parameters to predict survival and clinical responses of first-line chemotherapy for advanced gastric cancer.

Methods

Sample size estimation

Sample was estimated by statistical methods (http://powerandsamplesize.com/). Using the Cox PH, 2-Sided Equality Model online, the inputted parameters of estimated Hazard Ratio was 1.75 to 2.25 according to previous similar study on advanced GC [16], the overall probability of event was 0.8, proportion of samples in groups was 1:1. As a result, the estimated sample size ranged from 60 to 126 by the power of 0.8.

Patients and eligibility criteria

A retrospective analysis was performed based on the medical records at Nanfang Hospital, Guangzhou, China. From February, 2011 to August, 2017 at this center, there were 589 advanced gastric cancer patients who lost the radical resection opportunity. Among them, we only focused on the patients who initially treated with standardized palliative first-line chemotherapy with regular follow-up. Those patients who initially received second or more advanced line chemotherapy at our hospital were excluded from the study.

All the patients should have a Zubrod-ECOG (WHO) score ≤ 2. The histopathology diagnosis of gastric cancer was confirmed by at least two experienced pathologists in our hospital. According to WHO classification of stomach cancer histologic types, well differentiated is defined as being composed of well-differentiated adenoid structures, and intestinal metaplasia sometimes could be seen. Poorly differentiated is defined as being composed of irregular-differentiated glands and sometimes even hard to identify the adenoid structures. The microscopy appearance of moderately differentiated is between those of well differentiated and poorly differentiated. Patients had no history of hematological diseases. Antineoplastic therapies (chemotherapy, radiotherapy or immunotherapy, etc.) were not received within two months before the start of first-line chemotherapy, and other treatments that could affect bone marrow hematopoiesis were also not received before the start of first-line chemotherapy. The chemotherapy regimens were limited to the protocol of advanced gastric cancer recommended by guidelines of the Chinese Society of Clinical Oncology (CSCO), the National Comprehensive Cancer Network (US) (NCCN) and the European Society of Medical Oncology (ESMO). The patients changing the chemotherapy regimen before meeting the PD standard, or simultaneously receiving other antineoplastic therapy (including radiotherapy or immunotherapy, etc.) during the treatment, were excluded from the study. As a result, a total of 136 patients met the eligibility criteria and were included in the studies.

Follow-up and assessment

The response to treatment was assessed about every two cycles of three-week regimens or every four cycles of two-week regimens (i.e., every 6 to 8 weeks) on the basis of the rules established by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [24]. Baseline assessment was performed within 2 weeks before the first-line chemotherapy. The chemotherapy response status was defined as complete response (CR), partial response
(PR), stable disease (SD) and progressive disease (PD). Progression free survival (PFS) was calculated from the beginning of the first-line treatment until PD. Platelet counts, neutrophil, and lymphocyte values were collected before the initiation of first-line treatment.

**Statistical analysis**

Student’s t test or Analysis of variance (ANOVA) were used to compare PLR, NLR and the clinical pathologic characteristics. Correlation between NLR and PLR, and the disease control rate (DCR; the rate of CR + PR + SD) between groups were assessed by Pearson’s correlation analysis. Association between differentiation score and other parameters were assessed by Chi-square test. Survival analysis was carried out using Kaplan-Meier methods and compared by the Log-rank test. The receiver operating characteristic (ROC) curve was applied to determine the optimal continuous variables cut-off points based on the largest Youden’s index. The prognostic prediction priority of different clinical parameters was compared by areas under the ROC curve (AUC). Univariate and multivariate Cox-regression analyses were performed to identify the independent predictors for PFS. All analyses were performed using the SPSS 23.0 statistical software program (IBM, USA). All statistical tests used in this study were two-sided and \( P < 0.05 \) was considered statistically significant.

**Results**

**Clinicopathological characteristics**

A total of 136 patients with advanced gastric cancer were included in this study, which satisfied the estimated sample size. Therein, 82 (60.3%) were male and 54 (39.7%) were female. The median age at diagnosis was 55 years (range 28–85 years). There were 90 (66.2%) patients were poorly differentiated, while 46 (33.8%) were moderate or well differentiated. The patients received regimens include Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX), Capecitabine/Oxaliplatin (CapeOX), Paclitaxel or Docetaxel/Cisplatin (TP) and others. The PFS of all patients ranges from 30 to 703 days, and the median was 213 days (Fig. 1a). The median values of pre-treatment NLR and PLR were 2.60 and 181.14, respectively.

To investigate the associations of pre-treatment NLR and PLR with clinicopathologic characteristics of gastric cancer patients, comparisons between the different feature subgroups for NLR and PLR was carried out. We found that there was no significant difference of NLR and PLR in the different subgroups of gender, age, tumor differentiation and chemotherapy regimens (Table 1).

![Diagram](image_url)

**Fig. 1** Parameter definitions. a Progression-free survival during the first-line chemotherapy (1st PFS) curve for all the 136 patients included in this study. b Correlation analysis between NLR and PLR. c ROC curve for NLR and PLR to determine the cut-off values at the median 1st PFS. d Schematic figures of cNPLDS and risk classifications.
The two systemic indices NLR and PLR have close positive correlation ($r^2 = 0.25$, $P < 0.0001$; Fig. 1b).

According to tumor differentiation, patients were stratified into well (score 1), medium (score 2) and poor (score 3) differentiated groups. Assessed by Chi-square assay, there were no significant association between differentiation score and other clinical characteristics, including gender, age, tumor differentiation and chemotherapy regimens (Table 2).

The differentiation status and PLR are independent prognostic factors for the first-line chemotherapy response

To determine the cut-off points for the continuous variables, the ROC curves of NLR and PLR for the first-PFS were analyzed at the time point of overall median survival time (Day 213) (Fig. 1c). The optimal continuous variables cut-off points were determined by the largest Youden’s index. As results, the optimal cut-off points were 3.04 for NLR (sensitivity 55.0%, specificity 77.3%), and 223 for PLR (sensitivity 46.7%, specificity 79.5%). By this, the high value group was defined as greater than the cut-off points, whereas the low value was less than or equal to the cut-off points.

To find out the relationship between clinicopathological features and PFS, univariate analyses including gender, age, histological differentiation, NLR and PLR was performed. In results, histological differentiation, NLR and PLR were risk factors that significantly influenced PFS (Table 3). Next, histological differentiation, NLR and PLR were analyzed by multivariate Cox-regression model. We found that only differentiation status and PLR were the independent prognostic factors for PFS. Whereas, NLR had no independent prognostic value, though it was significantly associated with PFS in univariate analysis (Table 3). This made us curious whether combining these parameters together better predict the first-PFS.

The cNPS and cNPLDS indicates poor prognosis of the first-line chemotherapy

According to the cut-off values, we used cNPS to reflect NLR and PLR status, which was defined as follows: patient with both elevated NLR (>3.04) and PLR (>223) was assigned a score of 3; patient with only either one elevated index was 2; patient with neither elevated was 1. Among these patients, 69 patients (50.7%) were of cNPS 1, 32 patients (23.5%) were of cNPS 2, and 35

---

**Table 1** The clinical characteristics of 136 patients with advanced gastric cancer

| Characteristic       | Total $n=136$ (%) | NLR Mean ± SEM | NLR $P$ value | PLR Mean ± SEM | PLR $P$ value |
|----------------------|------------------|----------------|--------------|----------------|--------------|
| Gender               |                  |                |              |                |              |
| Male                 | 82 (60.3%)       | 3.36 ± 0.30    | 0.876        | 191.66 ± 11.84 | 0.115        |
| Female               | 54 (39.7%)       | 3.43 ± 0.37    |              | 222.64 ± 16.00 |              |
| Age                  |                  |                |              |                |              |
| ≤55 years            | 74 (54.4%)       | 3.55 ± 0.37    | 0.446        | 204.34 ± 12.45 | 0.966        |
| >55 years            | 62 (45.6%)       | 3.20 ± 0.24    |              | 203.51 ± 15.06 |              |
| Differentiation      |                  |                |              |                |              |
| Poor                 | 90 (66.2%)       | 3.59 ± 0.32    | 0.144        | 213.43 ± 10.70 | 0.169        |
| Moderate/Well        | 46 (33.8%)       | 2.99 ± 0.25    |              | 185.44 ± 19.07 |              |
| Chemotherapy regimen |                  |                |              |                |              |
| FOLFOX               | 40 (29.4%)       | 3.77 ± 0.52    | 0.158        | 209.31 ± 16.29 | 0.964        |
| CapeOX               | 26 (19.1%)       | 3.94 ± 0.70    |              | 200.37 ± 26.76 |              |
| TP                   | 21 (15.4%)       | 3.58 ± 0.42    |              | 210.15 ± 22.98 |              |
| Others               | 49 (36.1%)       | 2.71 ± 0.22    |              | 198.85 ± 15.84 |              |

---

**Table 2** The relationship between differentiation score and other clinical characteristics

| Characteristic        | Differentiation | Gender $P$ value | Poor | Moderate | Well | $P$ value |
|-----------------------|-----------------|-----------------|------|----------|------|-----------|
| Gender                |                 | 0.107           | 49 (59.8%) | 27 (32.9%) | 6 (7.3%) |           |
| Male                  |                 |                 | 27 (32.9%) | 27 (32.9%) | 6 (7.3%) |           |
| Female                |                 |                 | 41 (75.9%) | 12 (22.2%) | 1 (1.9%) |           |
| Age                   |                 | 0.284           | 53 (71.6%) | 17 (23.0%) | 4 (5.4%) |           |
| ≤55 years             |                 |                 | 53 (71.6%) | 17 (23.0%) | 4 (5.4%) |           |
| >55 years             |                 |                 | 37 (59.7%) | 22 (35.5%) | 3 (4.8%) |           |
| Chemotherapy regimen  |                 | 0.310           | 24 (60.0%) | 14 (35.0%) | 2 (5.0%) |           |
| FOLFOX                |                 |                 | 24 (60.0%) | 14 (35.0%) | 2 (5.0%) |           |
| CapeOX                |                 |                 | 17 (65.4%) | 9 (34.6%)  | 0 (0.0%) |           |
| TP                    |                 |                 | 16 (76.2%) | 5 (23.8%)  | 0 (0.0%) |           |
| Others                |                 |                 | 33 (67.3%) | 11 (22.4%) | 5 (10.2%) |           |
patients (25.8%) were of cNPS 3. Since histological differentiation was independent prognostic factors for the first-PFS, we then additionally introduced a new parameter cNPLDS by multiplying cNPS and the differentiation score together (Fig. 1d). Therein, 27 patients (19.85%) were of cNPLDS 1–2, 55 (40.44%) were of 3–4, and 54 (39.71%) were of 6–9. In the univariate analyses, both high cNPS and high cNPLDS showed significantly correlation with shorter first-PFS (Table 2). Accordingly, we classified patient risk of progression by cNPLDS (Fig. 1d).

All the significant parameters in univariate analysis were therefore evaluated in subsequent Kaplan-Meier survival analysis. Patients with poor differentiation gastric cancer had a significantly shorter PFS (median 182 days) than the moderate or well differentiations (median 413 days) (Fig. 2a). Patients with high NLR (> 3.04) or high PLR (> 223) were more easily to get chemo-resistance during the first-line therapy with median PFS 134 vs. 293 days and 134 vs. 265 days, respectively (Figs. 2b and c). Patients of cNPS 3 had the poorest PFS (median 110 day), while those of cNPS 1 had most favorable PFS (median 320 day). The curve of cNPS 2 lay between them (median 202 day) (Fig. 2d). As to cNPLDS, patients of cNPLDS 1–2 (low risk) demonstrated the best prognosis (median 449 day), the cNPLDS 3–4 (moderate risk) ones had shorter first PFS (median 231 day), and cNPLDS 6–9 (high risk) ones were the worst (median 135 day) (Fig. 2e).

### Table 3 Univariate and multivariate analyses of clinical parameters for PFS prediction

| Variables                              | Univariate analysis | Multivariate analysis |
|----------------------------------------|---------------------|----------------------|
|                                        | χ² | P value | Hazard ratio (95% CI) | P value |
| Gender (male vs. female)               | 0.041 | 0.838 | | |
| Age (≤55y vs. >55y)                    | 0.317 | 0.574 | | |
| Differentiation (Poor vs. Moderate/Well) | 11.79 | < 0.001 | 1.775 (1.168–2.697) | 0.007 |
| NLR (≤3.04 vs. > 3.04)                 | 18.03 | < 0.001 | 1.027 (0.949–1.111) | 0.506 |
| PLR (≤223 vs. > 223)                   | 10.66 | 0.001 | 1.003 (1.001–1.005) | 0.010 |
| cNPS (1 vs. 2 vs. 3)                   | 19.50 | < 0.001 | | |
| cNPLDS (1–2 vs. 3–4 vs. 6–9)           | 23.82 | < 0.001 | | |

**Fig. 2** PFS analysis by Kaplan-Meier curves. Kaplan-Meier curves for 1st PFS in patients categorized by (a) histological differentiation, (b) NLR level, (c) PLR level (d) cNPS and (e) cNPLDS.
Table 4 list the first response assessment during the chemotherapy cycles. Most of the patients were SD 73. 53%. Response outcome rates of CR and PR were 0% and 5.15% respectively in total. The DCR of higher NLR and PLR were significantly worse than the corresponding rest groups. For cNPS and cNPLDS, DCR decreased progressively along with the score elevation. However, no statistical significance was reached when grouped by tumor differentiation status.

The cNPLDS is superior in predicting the first-line chemotherapy response
To assess prognostic accuracy, we compared the AUC at the median (Day 213) of the first-PFS in all patients. The AUC for differential status, NLR and PLR were 0.607, 0. 632 and 0.650, respectively. When integrating NLR and PLR, the classification was greatly improved by cNPS with an AUC of 0.682. Additionally, when taking differential status into account together with cNPS, cNPLDS further improved AUC to 0.709 (Fig. 3a). Moreover, we also compare the AUC at the third quarter (Day 413) of PFS to see the longer effect. Similarly, cNPLDS (AUC = 0.762) is superior to differential status (AUC = 0.706), NLR (AUC = 0.663) and PLR (AUC = 0.665) alone, and integrated cNPS (AUC = 0.695) (Fig. 3b). The cNPLDS had the higher AUC value for the third quarter PFS than the median, suggesting cNPLDS was more accurate in the long-term prognostic prediction.

Discussion
Chemotherapy is the main treatment for advanced unresectable gastric cancer, and the sensitivity to first-line chemotherapy has a direct impact on overall survival prognosis [25]. In this study, we introduce a novel prognostic parameter cNPLDS, integrating systemic NLR and PLR and local tumor differentiation status to predict the PFS of the first-line chemotherapy in advanced gastric cancer. We proved that the AUC of cNPLDS is larger than NLR, PLR, and cNPS, showing its priority in predicting prognosis. In addition, as an adverse prognostic factor, cNPLDS covers more high-risk population, and further refines the hazard classification. Moreover, cNPLDS is an economical clinical tool, which just depends on the basic diagnostic indices and dispenses with additional examinations. Hence, it is easy to apply in the less developed areas, where gastric cancer is generally of high prevalence and high mortality.

Previously, many studies used peripheral blood routine examination indices, e.g. NLR or PLR, and their derived cNPS, as predictors for curative resected gastric cancer recurrence or overall survival [17–19, 23]. However, studies about these parameters for chemotherapeutic response prediction in advanced unresectable gastric cancer are not too much [26–28]. Recently, a study based on the REAL-2 trial advanced oesophago-gastric cancer population reported that elevated NLR status demonstrate a significant negative prognostic effect on the first-line chemotherapy response [26]. It was also demonstrated that F-NLR score, a combining score of NLR and fibrinogen, predicted the therapeutic response of advanced gastric cancer to chemotherapy or chemoradiotherapy [28]. Interestingly, another study of advanced gastric cancer showed an association between the mismatch repair system status and NLR, which both influence the PFS and overall survival (OS) [27]. This suggested that the great histopathological heterogeneity should not be overlooked. Therein, tumor differentiation is also one of the most basic histopathological index. Given these, the novel cNPLDS was introduced, which reflects both systemic immunological status and local pathological characteristics. In this study, such combination was showed to improve the prediction efficiency. Moreover, since cNPLDS is a complicated prognostic parameter, we believe it would be more stable than single index. No statistical correlation was found between tumor differentiation and NLR or PLR, which suggested

Table 4  Chemotherapy response assessment

| Differentiation status | PLR < 223 | PLR > 223 | NLR ≤ 3.04 | NLR > 3.04 | cNPS 1 | cNPS 2 | cNPS 3 | cNPLDS 1–2 | cNPLDS 3–4 | cNPLDS 6–9 |
|------------------------|----------|----------|------------|------------|--------|--------|--------|-------------|-------------|-------------|
| Total                  | 46       | 90       | 89         | 47         | 81     | 55     | 69     | 32          | 35          | 27          |
| CR                     | (0%)     | (0%)     | (0%)       | (0%)       | (0%)   | (0%)   | (0%)   | (0%)        | (0%)        | (0%)        |
| well/moderate          |          |          |            |            |        |        |        |             |             |             |
| poor                   |          |          |            |            |        |        |        |             |             |             |
| PR                     | 3        | 4        | 4          | 3          | 3      | 4      | 2      | 3           | 2           | 2           |
| (6.52%)                | (4.44%)  | (4.49%)  | (3.70%)    | (7.27%)    | (2.90%)| (9.38%)| (5.71%)| (7.41%)      | (1.82%)      | (7.41%)      |
| SD                     | 36       | 64       | 72         | 28         | 68     | 32     | 59     | 22          | 17          | 23          |
| (78.26%)               | (71.11%) | (80.89%) | (59.57%)   | (83.95%)   | (58.18%)| (85.51%)| (68.75%)| (48.57%)     | (85.19%)     | (83.64%)     |
| PD                     | 7        | 22       | 13         | 16         | 10     | 19     | 8      | 7           | 14          | 2           |
| (15.21%)               | (24.44%) | (14.61%) | (34.04%)   | (12.34%)   | (34.55%)| (11.59%)| (21.87%)| (40%)        | (7.41%)      | (14.55%)     |
| DCR                    | 84.78%   | 75.56%   | 85.39%     | 65.96%     | 87.65% | 65.45% | 88.40% | 78.13%      | 60%         | 92.59%      |
| P                      | 0.214    | 0.008    | 0.002      | 0.004      |        |        |        |             |             | 0.004       |
they were two relatively independent sets of mechanism that both influence therapeutic response. This is probably another reason why cNPLDS is superior to differential status, NLR, PLR or integrated cNPS.

It is known that inflammation accompanies along with cancer progression [10]. In addition to local inflammatory response, systemic inflammatory response is also an important prognostic factor in cancer. Many experimental studies documented that neutrophils, platelets and lymphocytes participate in the cancer generation or malignancy progression [29–31]. It was reported that local cancer associated neutrophils of N2 phenotypes promote tumor growth and invasion by altering the extracellular matrix and inhibiting the function of other immune cells [31]. Activated platelets, which release various growth factors and cytokines, promote tumor metastasis [32, 33], angiogenesis [32, 34], and chemoresistance [32, 35]. Platelets can help the circulating tumor cells forming cancer embolus, and protect them from the immunocytes [32, 36]. Recently studies showed that platelet activation triggered platelet-neutrophil interaction and alters the immunocyte subpopulations [37]. In this study, we found a close correlation between NLR and PLR, suggesting that peripheral circulating neutrophils and platelets may play a synergistic effect on primary chemoresistance. Conversely, lymphocytes possess anti-tumor effect [38]. We reported that platelets could enhance the differentiation and cytokine production of CD4⁺ T lymphocytes [39], which could be regarded as a physiological balance. However, when the balance is broken, like the increase of the neutrophils or platelets but decrease of lymphocytes, the systemic immunity will turn abnormal. This probably explains why high NLR, PLR or cNPS patients has shorter PFS.

In the cNPLDS, tumor differentiation status is a relative steady composition, while other elements of neutrophils, platelets and lymphocytes were dynamic. This made us curious whether intervention of the latter might cover the deficiency of poor differentiation status on prognosis. Recently, increasing clinical data showed that targets-PD-1 or PD-L1 treatment plus chemotherapy received more favorable efficiency [40], suggesting activating lymphocyte may be a promising approach for chemotherapy optimizing. Besides lymphocytes activation, we also wonder whether inhibiting neutrophils or platelets designedly to certain level or suppressing their activities may improve the therapeutic effect. Few studies explored pharmacological inhibition on neutrophils, which is probably because of catastrophic side effects, such as agranulocytosis or consequent sever infection. However, recent in vitro and in vivo study showed that some antiplatelet activation drugs, such as aspirin [41], P2Y12 inhibitor [42], and Integrin β3 inhibitors [43], may play tumor suppressive roles. Although some clinical trials reported the value of aspirin in cancer prevention and improving forward prognosis [44–46], there were also some negative results documented [47, 48]. On the other hand, there were no good indicators to determine which subgroups of patients might benefit from platelet intervention. This probably resulted in the trail failure. In this study, cNPLDS is introduced as a prognostic factor integrating platelets, neutrophils, lymphocytes and tumor differentiation, and we suppose that
those high cNPLDS patients may probably benefit from the pharmacological interventions. However, this need further studies and larger data to support.

Conclusion
In conclusion, our study demonstrates the novel parameter cNPLDS is superior to NLR or PLR alone, or their derived cNPS. The cNPLDS is a continent and economical prognostic predictor for the first-line chemotherapeutic response in advanced unresectable gastric cancer.

Abbreviations
ANOVA: Analysis of variance; AUC: Areas under the ROC curve; cNPLDS: Combined Neutrophil/platelet/lymphocyte/differentiation Score; cNPS: Combined NLR-PLR score; CR: Complete response; ECOG: The European Organization for Research and Treatment of Cancer; ESMO: The European Society of Medical Oncology; NCCN: The National Comprehensive Cancer Network (US); NLR: Neutrophil-to-lymphocyte ratio; PD: Progressive disease; PFS: Progression free survival; PLR: Platelet-to-lymphocyte ratio; PR: Partial response; RECIST: The Response Evaluation Criteria in Solid Tumors; ROC curve: Receiver operating characteristic curve; SD: Stable disease

Funding
This work was supported by the National Natural Science Foundation of China (81502535 to LL), China Postdoctoral Science Foundation (2017M622739 to LL), the Natural Science Foundation of Guangdong Province (2015A030310039 to LL), the Pearl River S&T Nova Program of Guangzhou (201806010104 to LL), the SCORE foundation (Y-MX2015–099 to LL), and the Special Foundation for National Clinical Specialties of China (to Department of Oncology, Nanfang Hospital).

Authors’ contributions
YL, ZH, CY and XL collected the data; LL, ZH and CP performed the statistical analysis, and LL, JR, NL and WL drafted the manuscript. All authors read and approved the final manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Nanfang Hospital Ethics Review Board.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Wu AW, Ji JF, Yang H, Li YN, Li LH. Long-term outcome of a large series of gastric cancer patients in China. Chin J Cancer Res. 2010;22(3):167–75.
2. Chen W, Zheng R, Baade PD, Zong S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
3. Sun LB, Zhao GJ, Ding DY, Song B, Hou RZ, Li YC. Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute. World J Surg Oncol. 2014;12:280.
4. Su Y, Lin L, Zhang J, Jiang Y, Pan C, Sun L, et al. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer. Mol Med Rep. 2015;12(4):5771–9.
5. Wang C, Wen Z, Xie J, Zhao Y, Zhao L, Zhang S, et al. MACC1 mediates chemotherapy sensitivity of S-FU and cisplatin via regulating MCT1 expression in gastric cancer. Biochem Biophys Res Commun. 2017;485(3):665–71.
6. Shi M, Huang W, Lin L, Zheng D, Zuo Q, Wang L, et al. Silencing of X1B130 is associated with both the prognosis and chemosensitivity of gastric cancer. PLoS One. 2012;7(8):e41660.
7. Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. 2015;33(16):1760–9.
8. Imrie CW. Host systemic inflammatory response influences outcome in pancreatic cancer. Pancreatology. 2015;15(4):327–30.
9. Aiken MD, Jones LJ. The role of inflammation in progression of breast cancer: friend or foe? (review). Int J Oncol. 2015;47(3):797–805.
10. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.
11. Zhang X, Zhang W, Yuan X, Fu M, Qian H, Xu W. Neutrophils in cancer development and progression: roles, mechanisms, and implications (review). Int J Oncol. 2016;49(3):857–67.
12. Xie G, Yao Q, Liu Y, Du S, Liu A, Guo Z, et al. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol. 2012;40(4):1171–9.
13. Li N. CD44+ T cells in atherosclerosis: regulation by platelets. Thromb Haemost. 2013;109(6):880–90.
14. Spectre G, Zhu L, Erosy M, Hjmdahl P, Savion N, Voran D, et al. Platelets selectively enhance lymphocyte adhesion on subendothelial matrix under arterial flow conditions. Thromb Haemost. 2012;108(2):328–37.
15. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27(5):553–61.
16. Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemoradiation. BMC Cancer. 2013;13:350.
17. Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in Resectable gastroesophageal junction and gastric adenocarcinoma. Ann Surg. 2016;263(2):292–7.
18. Jiang N, Deng JY, Liu Y, Ke B, Liu HG, Liang H. The role of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients after radical resection for gastric cancer. Biomarkers. 2014;19(6):444–51.
19. Hsu JT, Wang CC, Le PH, Chen TH, Kuo CJ, Lin CJ, et al. Lymphocyte-to-monocyte ratios predict gastric cancer surgical outcomes. J Surg Res. 2016;202(2):284–90.
20. Chrom P, Stec R, Bodnar L, Szczylk C. Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model. Cancer Res Treat. 2017;50(1):103–10.
21. Sun X, Liu X, Liu J, Chen S, Xu D, Li W, et al. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage III gastric cancer. Chin J Cancer. 2016;35(1):157.
22. Tajiri K, Baba H, Kawai K, Minemura M, Yasumura S, Takahara T, et al. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol Hepatol. 2016;31(7):1291–9.
23. Urabe M, Yamashita H, Umemura Y, Tanabe A, Yagi K, Akiko S, et al. Non-linear association between long-term outcome and preoperative neutrophil-to-lymphocyte ratio in patients undergoing curative resection for gastric cancer: a retrospective analysis of 1335 cases in a tetrachotomous manner. Jpn J Clin Oncol. 2018;48(4):343–9.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
25. Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, et al. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol. 2012;7(5):841–9.
26. Genader T, Waddell T, Peckitt C, Oates J, Starling N, Cunningham D, et al. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Ann Oncol. 2016;27(4):687–92.

27. Giampieri R, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, Faloppi L, et al. Mesenchymal repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer. 2017;20(1):156–63.

28. Arigami T, Uenosono Y, Ishigami S, Okubo K, Kijima T, Yanagita S, et al. A novel scoring system based on fibronectin and the neutrophil-lymphocyte ratio as a predictor of chemotherapy response and prognosis in patients with advanced gastric cancer. Oncology. 2016;90(4):186–92.

29. Liu Y, Yu Y, Han Y, Zhang Q, Jiang Z, Zhang X, et al. Tumor Exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 2016;30(2):243.

30. Glogauer JE, Sun CX, Bradley G, Magalhaes MA. Neutrophils increase oral squamous cell carcinoma invasion through an Invadopodia-dependent pathway. Cancer Immunol Res. 2015;3(11):1218–26.

31. Zou JM, Qin J, Li YC, Wang Y, Li D, Shu Y, et al. IL-35 induces N2 phenotype of neutrophils to promote tumor growth. Oncotarget. 2017;8(20):33501–14.

32. Li N. Platelets in cancer metastasis: to help the "villain" to do evil. Int J Cancer. 2016;138(9):2078–87.

33. Schumacher D, Strilic B, Sivaraj KK, Faloppi L, et al. IL-35 induces N2 phenotype of neutrophils to promote tumor growth. Oncotarget. 2017;8(20):33501–14.

34. Li N. Platelets in cancer metastasis: to help the "villain" to do evil. Int J Cancer. 2016;138(9):2078–87.

35. Ishikawa S, Miyashita T, Inokuchi M, Hayashi H, Oyama K, Tajima H, et al. Neutrophils increase oral squamous cell carcinoma invasion through an Invadopodia-dependent pathway. Cancer Immunol Res. 2015;3(11):1218–26.

36. Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, et al. Human neutrophils modulate tumor microenvironment by activating dendritic cells. J Immunother. 2017;40(5):428–38.

37. Schrottmaier WC, Kral JB, Badrnya S, Assinger A. Aspirin and P2Y12 inhibitors promote breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. Br J Cancer. 2017;117(5):695–703.

38. Schrottmaier WC, Kral JB, Badrnya S, Assinger A. Aspirin and P2Y12 inhibitors promote breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. Br J Cancer. 2017;117(5):695–703.

39. Gerdes N, Zhu L, Ersoy M, Hermansson A, Hjemdahl P, Hu H, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8.

40. Fuchs CS, Ohtsu A, Tabernero J, Cutsem EV, Wang JD, Lam B, et al. Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer. J Clin Oncol. 2016;34(15_suppl):4037.

41. Stark LA, Reid K, Sansom OJ, Din FV, Guichard S, Mayer I, et al. Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis. 2007;28(5):968–76.

42. Gebremeskel S, LeVatte T, Litwaki RS, Johnston B, Beuzly M. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015;136(1):234–40.

43. Wei Zhang SD, Hong T, Tang J, Fan J, Bu D, Sun Y, Wang Z, Wisniewski T. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood. 2014;123(2):302.

44. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603–13.

45. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.

46. Reimers MS, Bastiaannet E, Herk-Sukel MMP, Lemmens VEP, Breuk CBWV, Cramer AJMD, et al. Aspirin use after diagnosis improves survival in older adults with Colon Cancer: a retrospective cohort study. J Am Geriatr Soc. 2012;60(12):2232–6.

47. Serebruany VL, Cherepanov V, Cabrera-Fuentes HA, Kim MH. Solid cancers after antiplatelet therapy: confirmations, controversies, and challenges. Thromb Haemost. 2015;114(6):1104–12.

48. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.